Journal
JOURNAL OF VIROLOGY
Volume 86, Issue 6, Pages 3393-3397Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.06745-11
Keywords
-
Categories
Funding
- Vaccine Research Center, NIAID, NIH
Ask authors/readers for more resources
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are being considered for passive prevention of infection. We analyzed the interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-competition and displayed additive, though not synergistic, neutralization activity. Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available